CSIMarket
 
Concert Pharmaceuticals Inc   (CNCE)
Other Ticker:  
 
 
Price: $8.3700 $0.01 0.120%
Day's High: $8.55 Week Perf: -0.36 %
Day's Low: $ 8.35 30 Day Perf: -0.24 %
Volume (M): 10,733 52 Wk High: $ 0.00
Volume (M$): $ 89,837 52 Wk Avg: $0.00
Open: $8.38 52 Wk Low: $0.00



 Market Capitalization (Millions $) 416
 Shares Outstanding (Millions) 50
 Employees 107
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -186
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Concert Pharmaceuticals Inc
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat patients who are suffering from serious diseases by applying its deuterium chemistry technology. Deuterium is a naturally occurring and stable isotope of hydrogen. This technology enables the company to create new chemical entities with potential advantages across a range of therapeutic areas, including oncology, central nervous system disorders, and inflammation, among others.

The company was founded in 2006 and is headquartered in Lexington, Massachusetts. Its portfolio includes several drug candidates that are either in preclinical or clinical development phases. Their lead program, CTP-543, is an oral drug candidate for the treatment of moderate-to-severe alopecia areata (AA), an autoimmune disease that affects hair growth. It has completed Phase 2a clinical trials and has demonstrated positive results in reducing the severity of AA symptoms.

Another program in concert pharmaceuticals is the AVP-786 program focuses on treating neurologic and psychiatric conditions, such as Alzheimer's disease, schizophrenia, and bipolar disorder. It is a combination of two compounds, dextromethorphan and quinidine. The combination is designed to treat symptoms associated with these conditions by targeting the overactive N-methyl-D-aspartate (NMDA) receptors within the brain.

Concert Pharmaceuticals also has a partnership with Celgene, a subsidiary of Bristol-Myers Squibb, to develop CTP-730, a deuterium-modified version of apremilast. It is an oral medication that works by inhibiting phosphodiesterase 4 (PDE4) and reducing inflammation. The drug is currently in Phase 1 clinical trials for the treatment of moderate-to-severe psoriasis.

The company's approach to drug development is unique and innovative, and it is focused on developing deuterium-modified compounds as a means of improving the properties of molecules to produce safer and more effective drugs. They have received several patents for their deuterium chemistry technology.

Overall, Concert Pharmaceuticals Inc. is a promising biopharmaceutical company with a diverse pipeline of drug candidates that have the potential to transform the treatment of several serious diseases. Its focus on deuterium chemistry technology sets it apart from other pharmaceutical companies and provides an innovative solution to improving drug efficacy and safety.


   Company Address: 65 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 860-0045   Stock Exchange / Ticker: NASDAQ CNCE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Concert Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com